Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice

Journal of Gene Medicine

Volumn 9, Issue 11, 2007, Pages 986-993

  Bloquel, C ^a,b,c,d   Denys, A ^a,e,f   Boissier, M C ^a,e,f   Apparailly, F ^a   Bigey, P ^a,b,c,d   Scherman, D ^a,b,c,d   Bessis, N ^a,e,f  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f AVICENNE HOSPITAL   (France)

Author keywords

Collagen induced arthritis; Electrotransfer; Gene therapy; Optical imaging; Soluble TNF receptor

Indexed keywords

COLLAGEN; LUCIFERASE; PLASMID VECTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; GENE EXPRESSION; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; TRANSGENE;

ANIMALS; ANKLE; ARTHRITIS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; ELECTROPORATION; GENE EXPRESSION; GENE THERAPY; HUMANS; INFLAMMATION; JOINTS; MICE; PLASMIDS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

MUS;

EID: 36148986078     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1088     Document Type: Article

References (44)

1. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005; 11: S39-44.
2. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-160.
3. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 1999; 38(Suppl 2): 3-7.
4. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-196.
5. Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002; 69: 123-132.
6. Keffer J, et al. EMBO J 1991; 10: 4025-4031.
7. Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 2): ii43-47.
8. Sacre SM, et al. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005; 7: 1-20.
9. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125-1132.
10. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005; 34: 7-11.
11. Bendele AM, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648-2659.
12. Weinblatt ME, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. N Engl J Med 1999; 340: 253-259.
13. Zwerina J, et al. Single and combined inhibition of tumor necrosis factor, interieukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277-290.
14. Moreland LW, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147.
15. Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 2006; 45: 656-668.
16. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65: 661-694.
17. Bessis N, et al. Gene therapy in rheumatoid arthritis. J Gene Med 2002; 4:581-591.
18. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11(Suppl 1): S10-17.
19. De Laporte L, Cruz Rea J, Shea LD. Design of modular non-viral gene therapy vectors. Biomaterials 2006; 27: 947-954.
20. Cemazar M, et al. Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution. BMC Cancer 2004; 4: 81.
21. Rizzuto G, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999; 96: 6417-6422.
22. Mir LM, et al. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. C R Acad Sci III 1998; 321: 893-899.
23. Mir LM, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96: 4262-4267.
24. Khoury M, et al. A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. J Gene Med 2006; 8: 1027-1036.
25. Blair-Parks K, Weston BC, Dean DA. High-level gene transfer to the cornea using electroporation. J Gene Med 2002; 4: 92-100.
26. Inoue T, Krumlauf R. An impulse to the brain - using in vivo electroporation. Nat Neurosci 2001; 4(Suppl): 1156-1158.
27. Jaichandran S, et al. In vivo liver electroporation: optimization and demonstration of therapeutic efficacy. Hum Gene Ther 2006; 17: 362-375.
28. Maruyama H, et al. Skin-targeted gene transfer using in vivo electroporation. Gene Ther 2001; 8: 1808-1812.
29. Bloquel C, et al. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 2004; 15: 189-201.
30. Saidenberg-Kermanach N, et al. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 2003; 5: 164-171.
31. Schiffelers RM, et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 2005; 52: 1314-1318.
32. Bloquel C, et al. Optical imaging of luminescence for in vivo quantification of gene electrotransfer in mouse muscle and knee. BMC Biotechnol 2006; 6: 16.
33. Miellot A, et al. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 2005; 35: 3704-3713.
34. Grossin L, et al. Direct gene transfer into rat articular cartilage by in vivo electroporation. FASEB J 2003; 17: 829-835.
35. Ohashi S, et al. Successful genetic transduction in vivo into synovium by means of electroporation. Biochem Biophys Res Commun 2002; 293: 1530-1535.
36. Adriaansen J, et al. Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum Gene Ther 2006; 17: 985-996.
37. Goater J, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000; 27: 983-989.
38. Tomita T, et al. In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes. Arthritis Rheum 1997; 40: 901-906.
39. Chan JM, et al. Intraarticular gene transfer of TNFR: Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002; 6: 727-736.
40. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 2007; 7: 67-77.
41. Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J Gene Med 2004; 6(Suppl 1): S11-23.
42. Kon OL, et al. Naked plasmid-mediated gene transfer to skeletal muscle ameliorates diabetes mellitus. J Gene Med 1999; 1: 186-194.
43. Vacik J, Dean BS, Zimmer WE, Dean DA. Cell-specific nuclear import of plasmid DNA. Gene Ther 1999; 6: 1006-1014.
44. Brooks AR, et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395-404.